Asgard Therapeutics AB is pioneering the use of cellular reprogramming in cancer immunotherapy. The scientific founders of Asgard have developed a cellular reprogramming technology that forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. Asgard solution is an off-the-shelf cancer immunotherapy that can be administered to multiple patients inducing a personalized immune response. It can be applied to different cancers, representing a platform technology with vast economic potential.
Direct cell reprogramming technologies for cancer immunotherapy.
Founded by Filipe Pereira, Cristiana Pires and Fábio Rosa.
Portfolio company since 2018.
Portfolio Manager LU Holding:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78